HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
Open accessThe DOI matches its Crossref record; 95 of the 99 references it cites were found in a registry or an index; 48 of the 101 sources its claims cite were checked for support.
Abstract
Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide and available therapies, including immunotherapies, are ineffective for many patients. HCC is characterized by intratumoral hypoxia, and increased expression of hypoxia-inducible factor 1α (HIF-1α) in diagnostic biopsies is associated with patient mortality...
Overview
CoChat Summary
## TL;DR
This paper identifies 32-134D, a low-molecular-weight HIF inhibitor, as a suppressor of HCC growth that blocks both HIF-1 and HIF-2 activity in human and mouse HCC models. In immunocompetent Hepa1-6 mice, adding 32-134D to anti-PD1 increased complete tumor eradication from 25% to 67%.
## Key findings
- In hypoxic Hep3B cells, 32-134D significantly inhibited HIF-dependent reporter activity with an IC50 of 2.9 μM, and 252 analogs yielded 27 compounds with HIF-transcriptional IC50 values below 3.3 μM.
- In Hep3B xenografts, daily intraperitoneal 32-134D caused partial growth inhibition at 20 mg/kg and maximal inhibition at 40 and 80 mg/kg; treated tumors showed decreased mass and reduced CD31-positive blood vessel area.
- RNA-seq in hypoxic Hep3B cells showed that 3,326 of 3,849 hypoxia-induced genes (86%) were inhibited by 32-134D; overall, 4,689 genes were inhibited, and a 15-gene HIF signature was associated with survival of 364 HCC patients (82 months vs 42 months, P = 0.006).
- In syngeneic Hepa1-6 tumors, 32-134D increased complete responses to anti-PD1 from 25% (3/12) to 67% (8/12), while 32-134D alone eradicated tumors in 4 of 12 mice.
- 32-134D shifted the tumor immune microenvironment toward antitumor immunity: it increased CD8+IFN-γ+ effector T cells, activated CD8+ T cells, and activated NK cells, and decreased TAMs and M-MDSCs; the effector T-cell:TAM ratio increased 3-fold.
- Safety signals were limited in mice: no changes were seen in appearance, behavior, body weight, hemoglobin, hematocrit, serum EPO, or histology of brain, colon, heart, kidney, liver, lungs, or small intestine after 14 days at 40 or 80 mg/kg/day.
## Methods
- The study combined an NCI-60 virtual screen, chemical synthesis of lead analogs, in vitro reporter assays and RT-qPCR, mouse xenograft and syngeneic HCC models, flow cytometry, ELISA, immunohistochemistry, and RNA-seq.
- Human Hep3B and mouse Hepa1-6 HCC cells were used; Hep3B xenografts were grown in nude mice, and Hepa1-6 tumors were grown in C57L mice, with treatment by daily intraperitoneal 32-134D, anti-PD1, or both.
- Main analyses included FLuc/RLuc reporter assays under 1% O2, RT-qPCR/RNA-seq with differential expression thresholds of FDR < 0.05 and fold change > 1.5, tumor immune-cell profiling by flow cytometry, and pharmacokinetics by LC-MS/MS.
## Limitations
- The paper states that further studies are required to determine whether steady-state plasma levels of 32-134D are achieved with daily administration.
- The work is preclinical and limited to cell lines and mouse models; clinical efficacy in humans is not tested in the paper.
- Evident from the text: some mechanistic claims about stromal versus tumor-cell effects are inferential, because differential effects in tumors versus cultured Hepa1-6 cells suggest but do not directly prove the responsible cell types.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
24 Valid · 3 Not valid · 18 Not checked · 97 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Many patients may fail to respond to immune checkpoint inhibitors because of the coexistence of other mechanisms of immune evasion, such as the production of adenosine, which binds to its cognate receptor on T cells to trigger apoptosis (13), or the absence of sufficient T and NK cells in the tumor to serve as targets for anti-PD1 (14).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Disputedcites [13] Huang S et al Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion Blood 1997 90 4 1600 1610 9269779 sourceExperimental — accuracy not yet measured
The citation is attached to the claim that adenosine binds a T-cell receptor to trigger apoptosis, not to the separate claim about insufficient T and NK cells. The Abstract (page unavailable) reports A2a receptor-mediated inhibition of T-cell activation and proliferation at low extracellular adenosine concentrations, but explicitly says direct lymphotoxicity was not observed. It therefore does not support receptor-triggered apoptosis as the mechanism. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [14] Beatty GL Gladney WL Immune escape mechanisms as a guide for cancer immunotherapy Clin Cancer Res 2015 21 4 687 692 10.1158/1078-0432.CCR-14-1860 25501578 PMC4334715 sourceExperimental — accuracy not yet measured
The Tailoring cancer immunotherapy section (page unavailable) says tumors with weak lymphocyte infiltration may need treatment that brings tumor-specific T cells into the tumor before anti-PD-1 therapy can be effective. It does not identify a shortage of NK cells as a reason anti-PD-1 lacks targets. Adenosine production is attached to a different citation in the citing sentence, so it is not assessed here. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Hypoxia-inducible factors (HIFs) play critical roles in cancer progression by activating the transcription of a large battery of genes encoding proteins that play key roles in angiogenesis, glucose metabolism, invasion/metastasis, stem cell specification, protumoral inflammatory responses, and tumor immune evasion (18, 23–27).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Not checked — no full text of the sourcecites [18] Schito L Semenza GL Hypoxia-inducible factors: master regulators of cancer progression Trends Cancer 2016 2 12 758 770 10.1016/j.trecan.2016.10.016 28741521 source
- Supportedcites [23] de Heer EC et al HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer J Clin Invest 2020 130 10 5074 5087 10.1172/JCI137552 32870818 PMC7524491 source
The Introduction describes HIFs as important to cancer progression, and ‘HIF activity in breast cancer’ states that HIF induces transcription of target genes. The review also discusses HIF-linked angiogenesis, glucose metabolism, invasion and metastasis, breast cancer stem-cell traits, proinflammatory factors, and an immunosuppressive tumor microenvironment. The claim is a fair synthesis of those passages, though the review focuses on breast cancer; page numbers are not available for most passages in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [24] Samanta D Semenza GL Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors Biochim Biophys Acta Rev Cancer 2018 1870 1 15 22 10.1016/j.bbcan.2018.07.002 30006019 source
- Not checked — no full text of the sourcecites [25] Semenza GL Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors Physiology (Bethesda) 2021 36 2 73 83 33595388 source
- Partly supportedcites [26] Triner D Shah YM Hypoxia-inducible factors: a central link between inflammation and cancer J Clin Invest 2016 126 10 3689 3698 10.1172/JCI84430 27525434 PMC5096825 sourceExperimental — accuracy not yet measured
The Introduction describes HIFs as transcription factors and critical drivers of cancer that regulate metabolism, angiogenesis, and invasion/metastasis. The Conclusion and “Hypoxic regulation of tumor immune cell function” also connect HIF signaling to protumor inflammation and suppression of antitumor immunity. Our copy does not support the specific addition of stem cell specification to this list. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [27] Xiang L Semenza GL Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy Adv Cancer Res 2019 141 175 212 30691683 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intratumoral hypoxia is a major driving force for cancer progression (15–19).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Partly supportedcites [15] Bao MH Wong CC Hypoxia, metabolic reprogramming, and drug resistance in liver cancer Cells 2021 10 7 1715 10.3390/cells10071715 34359884 PMC8304710 sourceExperimental — accuracy not yet measured
Section 2 says intratumoral hypoxia in hepatocellular carcinoma induces metabolic changes that promote drug resistance. Section 3.1 links conditions in the tumor microenvironment to faster tumor progression. These passages support a role for hypoxia in progression, but do not establish that it is a major driving force for cancer progression generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [16] Harris AL Hypoxia—a key regulatory factor in tumour growth Nat Rev Cancer 2002 2 1 38 47 10.1038/nrc704 11902584 source
- Supportedcites [17] Hatfield SM Sitkovsky MV Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy J Clin Invest 2020 130 11 5629 5637 10.1172/JCI137554 32870821 PMC7598059 source
The Introduction says hypoxia-induced HIF-1α helps tumor cells adapt and thrive and strengthens immunosuppressive signaling. The section “Targeting immunosuppressive hypoxia/HIF-1α axis” also describes the protumor effects of hypoxia, supporting the broad claim that intratumoral hypoxia drives cancer progression. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [18] Schito L Semenza GL Hypoxia-inducible factors: master regulators of cancer progression Trends Cancer 2016 2 12 758 770 10.1016/j.trecan.2016.10.016 28741521 source
- Not checked — no full text of the sourcecites [19] Vaupel P et al Detection and characterization of tumor hypoxia using pO2 histography Antioxid Redox Signal 2007 9 8 1221 1235 10.1089/ars.2007.1628 17536958 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mouse models, hypoxic zones within tumors were shown to lack T cells (37, 38).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Partly supportedcites [37] Hatfield SM et al Immunological mechanisms of the antitumor effects of supplemental oxygenation Sci Transl Med 2015 7 277 277ra30 25739764 PMC4641038 sourceExperimental — accuracy not yet measured
The Results section reports markedly fewer CD4 and CD8 T cells in hypoxic tumor areas than in neighboring normoxic areas in mouse models. It does not say those areas lack T cells entirely. No page number is provided in our copy. (LLM, conf=0.88)
- Supportedcites [38] Jayaprakash P et al Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy J Clin Invest 2018 128 11 5137 5149 10.1172/JCI96268 30188869 PMC6205399 source
In the section “Hypoxic zones within prostate tumors lack T cells” and its continuation (page not specified in the excerpt), the authors report that T cells were largely excluded from hypoxic zones in two mouse models of prostate cancer. This supports the citing sentence’s claim about mouse models. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“B7H4 and TIM3 mRNA, which are encoded by the Vtcn1 and Havcr2 genes, respectively, and like PDL1, encode immune checkpoint receptors that are HIF regulated (51, 52) and associated with patient mortality in HCC (53), showed hypoxia-induced expression in vehicle-treated but not in 32-134D–treated cells (P < 0.05; Figure 3B).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Results > Effects of 32-134D on Hepa1-6 mouse HCC cells and tumors.
What the sources say
- Not checked — no full text of the sourcecites [51] Jeon YK et al Cancer cell-associated cytoplasmic B7-H4 is induced by hypoxia through hypoxia-inducible factor-1α and promotes cancer cell proliferation Biochem Biophys Res Commun 2015 459 2 277 283 10.1016/j.bbrc.2015.02.098 25725157 source
- Partly supportedcites [52] Koh HS et al The HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia Nat Commun 2015 6 6340 10.1038/ncomms7340 25790768 PMC4383004 sourceExperimental — accuracy not yet measured
The Results section, “TIM-3 is elevated in a HIF-1-dependent manner under hypoxia” (page unavailable), reports increased TIM-3 transcripts under hypoxia and HIF-1-dependent regulation in glial cells. It does not report B7H4 expression or the vehicle-versus-32-134D result in Hepa1-6 cells. In the citing sentence, the citations accompany the HIF-regulation background statement; Figure 3B accompanies the cell-treatment result. (LLM, conf=0.88)
- Supportedcites [53] Shrestha R et al Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma Front Oncol 2018 8 269 10.3389/fonc.2018.00269 30057891 PMC6053505 source
Citation 53 supports the sentence’s claim that B7-H4 and TIM-3 are associated with mortality in HCC patients. The Abstract reports that both were independently associated with worse prognosis, and the Discussion links each to worse overall survival. The hypoxia and 32-134D result is attributed to the citing paper’s Figure 3B, not to this source. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
85 more claims · 4 with their cited sources checked
Create a free account to see all 142 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 26
- Borderline: one of the tests for a substantial claim is unclear. 1
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF‐1α reverses immune dysfunction and overcomes resistance to PD‐L1 blockade.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thus, HIF-1/2α inhibition in mouse models of cancer promotes the efficacy of anti-PD1 therapy and increases infiltration of cytotoxic immune effector cells [84–86].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with this compound reduced HIF-1α and, to a lesser extent, HIF-2α protein levels without altering HIF1A or EPAS1 mRNA expression.”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [334]
The cited source says what the claim attributes to it.
In the citing paper
“the small molecule 32-134D was identified as suppressing HIF-α accumulation in hepatocellular carcinoma cell lines.”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [334]
The cited source says what the claim attributes to it.
In the citing paper
“Proteasome inhibition abrogated this effect, suggesting enhanced proteasomal turnover of HIF-α subunits, although direct measurements of protein half-life were not performed [334].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [334]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Discussion
“In particular, the efficacy of many immunotherapies is dependent on the presence of intratumoral CD8+ T cells, which are significantly increased by treatment with 32-124D.”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Abstract
“Here we report the development of 32-134D, a low-molecular-weight compound that effectively inhibits gene expression mediated by HIF-1 and HIF-2 in HCC cells, and blocks human and mouse HCC tumor growth.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“We previously screened a library of 3,140 drugs and identified acriflavine as a drug that inhibits HIF activity by disrupting subunit dimerization, and blocks HCC tumor growth and vascularization in mouse models (41).”
Cited work 10.1073/pnas.0909353106 · retracted 2023-04-26 · notice 10.1073/pnas.2305537120 · this paper published 2022-05-02
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451 · cited 1×
“We previously screened a library of 3,140 drugs and identified acriflavine as a drug that inhibits HIF activity by disrupting subunit dimerization, and blocks HCC tumor growth and vascularization in mouse models (41).”
BackgroundSelf-citationRetractedModerated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219 · cited 1×
“quantified with featureCounts (94), and differential gene expres-”
MethodSorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 1×
“5-month improvement in progression-free survival as compared with sorafenib, although more than half of patients receiving the combination therapy suffered grade 3 or 4 adverse events (11).”
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055 · cited 1×
“Nivolumab, an anti-PD1 antibody, was granted FDA approval for HCC based on phase II trial data, but a phase III trial versus sorafenib as first-line therapy did not meet its primary endpoint with respect to overall survival (OS), and a phase III trial of pembrolizumab, another anti-PD1 antibody, also failed versus pla…”
Research works printed but not linked: 1
- National Research Council. Guide for the Care and Use of Laboratory Animals. National Academies Press; 2011. 21595115
Cited by
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
“For instance, 32–134D, a low-molecular-weight compound that inhibits HIF-1/2-mediated gene expression in HCC cells, combined with anti-PD-1 increased HCC eradication rates in mice (from 25 to 67%).(401) HIF-1α inhibitors, such as topotecan, bortezomib (PS-341) as well as HIF-2α inhibitors, such as PT2399, PT2385 and P…”
BackgroundHypoxia-inducible factors: cancer progression and clinical translation
Wicks, E. E., & Semenza, G. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159839 · Cited by 580
“In immunocompetent mice bearing Hepa1-6 mouse HCC tumors, combined treatment with 32-134D and anti–PD-1 antibody resulted in tumor eradication in 67% of the mice compared with 25% of the mice treated with anti–PD-1 alone (177).”
BackgroundInfluentialSelf-citationPD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Li, Q., Han, J., Yang, Y., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070961 · Cited by 246
Self-citationTargeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
“Thus, based on its similarity in gene target induction to acriflavine, 32-134D was recently identified as a nonspecific HIF inhibitor with a chemical structure unrelated to that of acriflavine 59 .”
InfluentialHypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Glucose metabolism of TAMs in tumor chemoresistance and metastasis
Liu, J., & Cao, X. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.03.008 · Cited by 129
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 164
“In addition, mice treated with a HIF inhibitor presented increased in fi ltration of NK cells in parallel with better outcomes in response to PD-1 therapy [240].”
Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy
Shurin, M. R., & Umansky, V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159473 · Cited by 113
Fu, Y., Mackowiak, B., Feng, D., Lu, H., Guan, Y., Lehner, T., Pan, H., Wang, X. W., He, Y., & Gao, B. (2023) · Gut · doi:10.1136/gutjnl-2022-327924 · Cited by 271
Ibrahim, A., Abdalsalam, N. M. F., Liang, Z., Tariq, H. K., Li, R., Afolabi, L. O., Rabiu, L., Chen, X., Xu, S., Xu, Z., et al. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00886-9 · Cited by 101
“Overexpression of DKK1 in conditions like HNSCC and HCC correlates with increased tumor growth and elevated PD-L1 expression, indicative of a cold tumor phenotype characterized by MDSC abundance and diminished CD8 + T cell in fi ltration [166].”
Targeting lactate metabolism for cancer immunotherapy - a matter of precision
Heuser-Loy, C., Renner, K., Kreutz, M. P., & Gattinoni, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.001 · Cited by 82
Advances in targeting tumor microenvironment for immunotherapy
Wang, L., Zhang, L., Zhang, Z., Wu, P., Zhang, Y., & Chen, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1472772 · Cited by 111
“This action halts the growth of human and murine HCC tumors, increasing the elimination rate from 25% to 67% (59).”
BackgroundThe HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects
Shi, Y., & Gilkes, D. M. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05537-0 · Cited by 90
Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer
Din, S. M. U., Streit, S., Huynh, B. T., Hana, C. K., Abraham, A. N. J., & Hussein, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042060 · Cited by 70
Lactate: a rising star in tumors and inflammation
Liu, H., Pan, M., Liu, M., Zeng, L., Li, Y., Huang, Z., Guo, C., & Wang, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1496390 · Cited by 244
“Recent studies showed that targeting HIF-1 a could increase CD8 + T cell in fi ltration and support anti-PD-1/PD-L1 treatment as effectively as CTLA-4 blockade (89, 90).”
Locatelli, F., Minutolo, R., Nicola, L. D., & Vecchio, L. D. (2022) · Drugs · doi:10.1007/s40265-022-01783-3 · Cited by 58
“Another molecule was shown effective in a murine model of hepatic cell carcinoma [152].”
BackgroundTargeting intratumoral hypoxia to enhance anti-tumor immunity
Semenza, G. L. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.09.002 · Cited by 53
Self-citationImmunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy
Zhang, H., Fan, J., Kong, D., Sun, Y., Zhang, Q., Xiang, R., Lu, S., Yang, W., Feng, L., & Zhang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02460-1 · Cited by 58
“Significantly, it synergizes with ICB, enhancing tumor eradication rates in murine models [439].”
Croft, W. D., Pearce, H., Margielewska‐Davies, S., Lim, L., Nicol, S. M., Zayou, F., Blakeway, D., Marcon, F., Powell-Brett, S. F., Mahon, B. S., et al. (2023) · eLife · doi:10.7554/elife.86125 · Cited by 49
Zhou, K., Liu, X., & Zhu, H. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01752-9 · Cited by 64
“To address these challenges, emerging strategies are focused on modulating hypoxia to enhance drug efficacy, such as HIF-1α inhibition or the development of hypoxia-activated prodrugs [191–193].”
Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC
Horvath, L., Puschmann, C., Scheiber, A., Martowicz, A., Sturm, G., Trajanoski, Z., Wolf, D. G. F., Pircher, A., & Salcher, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.010 · Cited by 40
Song, C. W., Kim, H., Cho, H., Kim, M., Paek, S.-H., Park, H. J., Griffin, R. J., Terezakis, S. A., & Cho, L. C. (2022) · Cancers · doi:10.3390/cancers14133273 · Cited by 38
“Small-molecule HIF-2α inhibitors such as PT2399, PT2977 and 32–1340 have been shown to poses significant anti-tumor properties and enhance the efficacy of immune checkpoint inhibitors [43,68,69].”
BackgroundTumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma
Li, Z., Zhang, Z., Fang, L., Zhao, J., Niu, Z., Chen, H., & Cao, G. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s436962 · Cited by 43
Zhang, J., Sharma, D., Dinabandhu, A., Sanchez, J. C., Applewhite, B. P., Jee, K. J., Deshpande, M. M., Flores‐Bellver, M., Hu, M.-W., Guo, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163290 · Cited by 37
“We therefore examined the safety and efficacy of an HIF inhibitor, 32-134D, which reproduces acriflavine’s inhibition of HIF-regulated genes, but is structurally distinct from acriflavine (44).”
InfluentialSelf-citationHypoxia-Induced Signaling in Gut and Liver Pathobiology
Solanki, S. A., & Shah, Y. M. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051122-094743 · Cited by 38
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy
Khouzam, R. A., Lehn, J., Mayr, H., Clavien, P., Wallace, M. B., Ducreux, M. P., Limani, P., & Chouaïb, S. (2023) · Cancers · doi:10.3390/cancers15041235 · Cited by 39
Shafqat, A., Omer, M. H., Ahmed, E. N., Mushtaq, A. H., Ijaz, E., Ahmed, Z., AlKattan, K. M., & Yaqinuddin, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200941 · Cited by 36
“Combining 32-134D with anti-PD-1 immune checkpoint inhibitors (ICIs) enhances therapy response (32).”
BackgroundLuo, H., Wang, Q., Yang, F., Liu, R. R., Gao, Q., Cheng, B., Lin, X., Huang, L., Chen, C., Jin, X., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.164968 · Cited by 220
“A recent study showed that combining HIF inhibitor 32-134D with anti–PD-1 may represent a breakthrough therapy for HCC (48).”
New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow
Becht, R., Kiełbowski, K., & Wasilewicz, M. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031456 · Cited by 31
“Inhibition of HIF by a 32–134D compound and in combination with anti-PD-1 showed significant tumor eradication in mouse models [167].”
BackgroundLin, Y., Ou, D., Su, Y., Hsu, C., Hsiao, C., Ko, B., Chen, S., Wang, H.-W., Wang, J., Wu, Y., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.035 · Cited by 41
Barakat, R., Chatterjee, J., Mu, R., Qi, X., Gu, X., Smirnov, I., Cobb, O. M., Gao, K., Barnes, A., Kipnis, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54569-4 · Cited by 27
“In contrast to previous studies in which ICI therapy results in increased CD8 + T cell-mediated tumor cell death (killing) 38,39 , we observed no increase in tumor apoptosis (Supplementary Fig.”
Origins and molecular effects of hypoxia in cancer
Rey-Keim, S., & Schito, L. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.10.001 · Cited by 28
Désert, R., Giannone, F., Saviano, A., Hoshida, Y., Heikenwälder, M. F., Nahon, P., & Baumert, T. F. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00018-y · Cited by 26
Halpin-Veszeleiova, K., Mallouh, M. P., Williamson, L. M., Apro, A. C., Botticello-Romero, N. R., Bahr, C., Shin, M., Ward, K. M., Rosenberg, L., Ritov, V. B., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174675 · Cited by 205
“These studies established Our strategy to target tumor hypoxia to improve cancer immunotherapy is also supported by pioneering work by Semenza’s group using pharmacological agents to target HIFs (73, 74).”
Huang, M., Yang, S., Tai, W., Zhang, L., Zhou, Y., Cho, W. C. S., Chan, L., & Wong, S. C. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108720 · Cited by 20
“Such agents include MD6482, PT2385, ABT-869 (mTOR inhibitor); MD6482 has only been u ed clinically in patie ts with advanced renal cancer, while the other drugs are cur ently only being trialed in preclinical models [35,40].”
BackgroundZhong, J., Tian, L., Gou, Y., Zhao, P., Dong, X., Guo, M., Zhao, G., Li, A., Hao, A., He, T., et al. (2023) · Cancer & Metabolism · doi:10.1186/s40170-023-00310-6 · Cited by 19
“Hepatocellular carcinoma (HCC) is the most predominant type of primary liver cancer and the third leading cause of cancer-related mortality in the world [6, 7].”
Rashid, M. M., Corbin, B. A., Jella, P. K., Ortiz, C. J., Samee, M. A. H., Pautler, R. G., & Allen, M. J. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10373 · Cited by 21
Zhao, F., Yue, Z., Zhang, L., Qi, Y., Sun, Y., Wang, S., & Tian, Q. (2025) · Journal of Innate Immunity · doi:10.1159/000546476 · Cited by 25
“The HIF inhibitor 32-134D developed by Salman et al. [106] simultaneously targets HIF-1α and HIF-2, blocks lactate-mediated immunosuppressive signaling, and demonstrates significant hepatocellular carcinoma clearance efficacy when combined with anti-PD-1 therapy.”
Feng, Z., Chan, Y.-T., Lu, Y., Wu, J., Xing, T., Yuan, H., Feng, Y., & Wang, N. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155913 · Cited by 20
Sharma, D., Lau, E., Qin, Y., Jee, K. J., Rodrigues, M. W., Guo, C., Dinabandhu, A., McIntyre, E., Salman, S., Hwang, Y., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322759121 · Cited by 25
“Instead, we took advantage of a recently developed pharmacologic HIF inhibitor, 32 - 134D (40), which was reported to effectively inhibit HIF - 1 α and HIF - 2 α protein accumulation, resulting in a modest but broad reduction of dozens of HIF - regulated vasoactive mediators following intraocular…”
Self-citationRoles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies
Xiao, C., Liu, S., Ge, G., Jiang, H., Wang, L., Chen, Q., Jin, C., Mo, J., Li, J., Wang, K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1086813 · Cited by 18
“For example, HIF inhibitor 32-134D was found to eradicate murine hepatocellular carcinoma in combination with anti-PD1 therapy (Salman et al., 2022).”
BackgroundSchwarz, J., Rühle, J., Stephan, K., Dietz, S., Geißert, J., Schoppmeier, U., Frick, J.-S., Hudalla, H., Lajqi, T., Poets, C. F., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202250144 · Cited by 16
New insights into fibrotic signaling in hepatocellular carcinoma
Liang, S., Wang, F., Xue, W., Zhai, D., Liu, J., & Lv, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1196298 · Cited by 15
Yang, Y., Chen, C. O., Lyu, Y., Gololobova, O. A., Guo, X., Huang, T. Y.-T., Ramu, V. K., Talwar, V., Wicks, E. E., Salman, S., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci190470 · Cited by 16
Self-citationBeyoğlu, D., Huang, P., Skelton-Badlani, D., Zong, C., Popov, Y. V., & Idle, J. R. (2023) · Cells · doi:10.3390/cells12030485 · Cited by 13
“The question remains: what role, if any, did enhanced ascorbate production play in the generation of these tumors on the cirrhotic background at 24 week when maximum metabolic remodeling had occurred from hexose metabolism to ascorbate synthesis? The recent report of a low-molecular-weight inhibitor 34-132D of gene tr…”
BackgroundAssociations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
“Salman et al. reported the development of 32-134D, a low-molecular-weight compound that suppressed the expression of genes regulated by HIF-1/2 in cancerous cells and prevented tumor growth [160].”
BackgroundJacquemin, C., Orch, W. E., Diaz, O., Lalande, A., Aublin‐Gex, A., Jacolin, F., Toesca, J., Si‐Tahar, M., Mathieu, C., Lotteau, V., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05361-6 · Cited by 14
“Given the role of HIFs in tumor development, drugs that block their transcriptional activity or promote their degradation have been developed and are under clinical evaluation [12, 15].”
Guo, C., Niu, Y., Pan, X., Sharma, D., Lau, E., Yang, J., Luxardi, G., Amanullah, M., Lo, K., Moshiri, A., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq5355 · Cited by 16
Li, K., Yang, Y., Ma, M., Lu, S., & Li, J. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03090-x · Cited by 13
“HCC is characterized by intratumoral hypoxia [5].”
Self-citationShi, G., Liu, X., Du, Y., & Tian, J. (2024) · iScience · doi:10.1016/j.isci.2024.109062 · Cited by 12
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771365 · Cited by 11
“This combination therapy also promoted durable immune memory, preventing tumor recurrence (226).”
Meng, J., Chen, M., Gu, F., Miao, Y., Ji, Z., Lv, X., Tao, X., Li, J., Tian, Z., Wang, M., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114168 · Cited by 13
Shen, S., Xu, Y., Gong, Z., Teng, Y., Qiao, D., Huang, Y., Zhang, Z., Gao, J., Ni, H., Jin, Z., et al. (2022) · Aging and Disease · doi:10.14336/ad.2022.0826 · Cited by 11
“HIF-1α is the main regulator of cellular homeostasis and the organismal responses to hypoxia [21].”
Guo, Y., Gong, B., Li, Y., Lou, J., Shan, S., Zhang, X., Lü, Q., Zhu, D., Sun, Q., Miao, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202506165 · Cited by 14
Chu, X., Ma, J., Li, S., Wang, M., Tian, Y., & Lv, C. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02570-4 · Cited by 15
“Notably, when combined with PD-1 blockade, HIF inhibition significantly improved tumor clearance, increasing the tumor eradication rate from 25% to 67% [290].”
Shan, L., Gong, M., Zhai, D., Meng, X., Liu, J., & Lv, X. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03416-5 · Cited by 14
“The expression of CD73 is regulated by HIF-1, transforming growth factor (TGF)-β, EGFR, AKT, β-catenin, and other molecules, especially HIF-1, which plays the function of a transcription factor [46].”
Tumor hypoxia shapes natural killer cell anticancer activities
Retamal, M. A., Salazar‐Onfray, F., González, F. E., & Tittarelli, A. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02557-6 · Cited by 10
“…suppresses HIF-1a and HIF-2a-mediated gene expression of angiogenic and immunosuppressive genes (e.g., VEGFA, CD73, and PD-L1), decreased infiltration of TAMs and MDSCs, and increased presence of CD8 + T and NK cells within the TME, reducing tumor growth in both human and murine HCC models [225].”
Devi, D., Sharma, K., Khan, T., Rani, H., Rana, R., Sharma, H., Kaur, P., Prajapati, L., Rizwan, A., Allieu, M., et al. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156271 · Cited by 13
Hu, L., Wang, Z., Liao, Y., Jiang, X., Lian, H., & Lin, Z. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000041 · Cited by 10
Yousef, E. H., Gayar, A. M. E., & El‐Magd, N. F. A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03530-9 · Cited by 10
“Also, Salman et al. (2022) found that systemic HIF inhibition in HCC increases the expression of CXCL9 and CXCL10 and relieves immunosuppression by enhancing CD8 + T cells and NK cells recruitment to the tumor (Salman et al. 2022).”
The important role of myeloid-derived suppressor cells: From hepatitis to liver cancer
Li, S., Zhang, J., Wang, W., Zhang, Z., Huang, W., & Xia, L. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189329 · Cited by 11
Zhang, F., Wu, Z., Xiang, Y., He, Q., Li, W., Yang, K., & Yang, Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02527-4 · Cited by 15
“Numerous approaches targeting angiogenesis have shown limited success in the clinical application of HCC [5, 6], Therefore, It remains crucial to investigate the underlying molecular mechanisms that drive abnormal vascularization in liver cancer.”
Self-citationDevelopment of small molecule inhibitors of hypoxia-inducible factors for cancer therapy
Semenza, G. L. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100075 · Cited by 12
Self-citationOh, T., Kim, M.-W., Kang, G.-S., Ye, S., Choi, C., Park, W., Hay, M. P., Hirata, H., & Ahn, G. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2025.200 · Cited by 8
“Combining 32-134D with anti–PD-1 antibodies has resulted in a significant abrogation of tumor growth although 32-134D or anti–PD-1 antibodies themselves also offered very potent antitumor activities in that model [101].”
Li, Q., & Ramli, N. N. N. (2025) · Journal of Molecular Pathology · doi:10.3390/jmp6040025 · Cited by 7
Targeting conserved domains of hypoxia-inducible factors for cancer therapy
Salman, S., Huang, T. Y., Hwang, Y., Kumar, A., Datan, E., Wicks, E. E., Cho, E., Lee, S. N., Chen, C. O., Peng, Y., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20251009 · Cited by 11
“…are downstream of the ENO1 HRE and a basal SV40 promoter; and control reporter plasmid pSV-RL, in which Renilla luciferase (RLuc) coding sequences are downstream of the SV40 promoter only, such that the FLuc/ RLuc ratio served as a measure of HIF-1 transcriptional activity (Salman et al., 2022).”
InfluentialSelf-citationZhang, H., Han, B., Tian, S., Gong, Y., & Liu, L. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5693 · Cited by 9
“Currently, there is a shortage of safe and effective medications to prevent HCC recurrence and that exert long‑lasting results, and surgical intervention remains the primary preference for the clinical management of HCC (4,5).”
BackgroundKhouzam, R. A., Salman, S., Thiery, J., Zaarour, R. F., Vela, V., Limani, P., Janji, B., & Chouaïb, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093873 · Cited by 7
“…reduces HIF-1 α and HIF-2 α protein accumulation, impairs the recruitment of HIF complexes and coactivator p300 to hypoxia-responsive elements, and suppresses a large fraction of the hypoxia-induced transcriptome, including genes controlling angiogenesis, metabolism, and immune regulation [123].”
InfluentialSelf-citationHCC-derived CX3CL1 affects hepatocellular carcinoma prognosis and CX3CR1 + MDSC infiltration
Zhang, X., Lou, Y., Zheng, S., & Chang, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02410-z · Cited by 7
“…the recruitment of immune cells through the CX3CL1-CX3CR1 axis [9], blocking the HIF pathway, which regulates immune cell recruitment through CX3CL1, may promote the antitumor immune response by decreasing MDSC and TAM recruitment while increasing the number of CD8 + T cells and NK cells [39].”
Zhang, J., Yan, C., Wang, Y., Gao, M., Han, J., Zhang, M., Chen, Y., & Zhao, L. (2025) · Academic Radiology · doi:10.1016/j.acra.2025.02.042 · Cited by 6
Clinical investigation of hypoxia-inducible factors: getting there
Semenza, G. L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176253 · Cited by 5
“…of many types, including breast, colorectal, and liver cancer, to evade killing by the immune system and that small-molecule inhibitors of HIF-1 and HIF-2 dramatically improve the response to immune check-point inhibitors (anti-CTLA4, anti–PD-1 or anti–PD-L1 antibody) in mouse models (13, 14).”
Self-citationZhao, Y., Zhu, W., Dong, S., Zhang, H., & Zhou, W. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16873 · Cited by 6
“Similarly, treatment of HCC with HIF inhibitors in combination with anti- PD-1 elevated levels of immunostimulatory NK cells and CD8+ T cells in HCC while diminishing immunosuppressive TAMs [54].”
Xu, H., Ma, Y., Shao, L., Fu, Y. S., Luo, B., Xia, C., & Min, X. (2025) · Journal of Cancer · doi:10.7150/jca.102256 · Cited by 5
“International Publisher immunotherapy; however, no definitive cure is available in clinical practice, with surgical resection remaining the most effective treatment option [3].”
InfluentialHIF inhibition: Current strategies and clinical challenges
Więch-Walów, A., Bartoszewska, S., Barton, A., Czechowicz, P., Dudzik, J., Wielockx, B., Collawn, J. F., & Bartoszewski, R. (2026) · Redox biology · doi:10.1016/j.redox.2026.104220 · Cited by 3
“Proteasome inhibition abrogated this effect, suggesting enhanced proteasomal turnover of HIF-α subunits, although direct measurements of protein half-life were not performed [334].”
MicroRNA-223: a key regulator of liver tumour microenvironment
Avila, M. A. (2023) · Gut · doi:10.1136/gutjnl-2022-329322 · Cited by 3
The Role of Intra-Tumor Hypoxia in Cancer Cells Immune Escape Mechanism
Farhangnia, P., Delbandi, A., Aghamohamadi, N., Safdarian, A. R., & Akbarpour, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_61-1 · Cited by 4
The Effects of Hypoxia on the Immune–Metabolic Interplay in Liver Cancer
He, Y., Han, X., Liu, Y., Kempa, S., Vechiatto, C., Schmidt, R., Yilmaz, E. Y., Heidemann, L., Schnorr, J., Metzkow, S., et al. (2024) · Biomolecules · doi:10.3390/biom14081024 · Cited by 6
Tang, Z., Dai, T., Wu, S., Chen, X., Lv, B., Cui, D., Luo, R., Zhan, H., Liu, Y., Tang, Y., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114320 · Cited by 2
HIF-1–mediated ISG20 expression promotes breast cancer stemness and immune evasion
Yang, Y., Zuo, Q., Ramu, V., Talwar, V., Lv, Y., Chen, C. O., Drehmer, D., Huang, T., Salman, S., Dordai, D. I., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250777 · Cited by 4
Self-citationImmunometabolic heterogeneity in hepatocellular carcinoma: Transforming cold tumors into hot tumors
Xu, Y., & Sun, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105123 · Cited by 3
Wu, Y., Chen, X.-D., Chen, Z., Sun, R., Zhang, Q., Zengin, G., & Li, M. (2026) · BioFactors · doi:10.1002/biof.70126 · Cited by 3
Gao, K., Li, Y., Song, X., Ju, M., Liu, W. T., Xu, J., Jie, L., Zhang, H., Wei, Q., & Zhao, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108307 · Cited by 5
Immune microenvironment and progress in immunotherapy of cholangiocarcinoma
Shao, X. (2023) · Clinical Immunology Communications · doi:10.1016/j.clicom.2023.11.002 · Cited by 1
Wang, Z., Zou, T., Liao, C.-W., Li, X., Liu, Z., Liu, Z., & Chen, J. (2025) · Pharmaceuticals · doi:10.3390/ph18091299 · Cited by 1
“As demonstrated by Salman et al., PD-1-treated hepatocellular carcinoma mice showed no meaningful correlation with body weight, activity patterns, physical appearance, or hematocrit levels [43].”
Mei, H., & Yan, N. (2026) · Gene · doi:10.1016/j.gene.2026.150107 · Cited by 2
Hypoxia-driven tumor immune escape: mechanisms and therapeutic opportunities
Qin, H., 杨书强, He, J., Zhao, M., Zhao, L., Wang, J., Jiang, X., Chen, X., & Xu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1893099 · Cited by 1
“It also reduces TAMs and MDSCs while increasing CD8+ T cell and NK cell in fi ltration, helping convert cold tumors into hotter tumors (70).”
Li, K., Qin, Y., & Ye, L. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006648 · Cited by 1
Hypoxia in Drug Resistance and Radioresistance
Chang, K., Lin, I., & Cheung, C. H. A. (2023) · Springer eBooks · doi:10.1007/978-981-99-0313-9_19 · Cited by 1
Ebner, L. J. A., Imsand, C., Karademir, D., Peters, F., Kiessling, E., Fottner, A., Matter, C., Fajardo, D. S., Merolla, L., Wögenstein, G. M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.044 · Cited by 2
Systemic hypoxia suppresses solid tumor growthPreprint
Midha, A. D., Chew, B. T. L., Choi, B. G., Suh, J. M., Carpenter, C., Baik, A. H., Joshi, T., Blume, S. Y., Haribowo, A. G., Ruivo, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.09.704975 · Cited by 1
Luo, H., Wang, Q., Yang, F., Liu, R. R., Gao, Q., Cheng, B., Lin, X., Huang, L., Chen, C., Jin, X., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4182425
Shah, D. D., Dave, B. P., Patel, P. A., Chorawala, M. R., Patel, V. N., Shah, P. A., & Patel, M. P. (2023) · Medical Oncology · doi:10.1007/s12032-023-01948-4 · Cited by 3
Guangyuan, S., Liu, X., Du, Y., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4580463
Natural product target on HIF inhibition
Wang, X. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/21/20230867
Halpin-Veszeleiova, K., Mallouh, M. P., Apro, A. C., Romero, N., Bahr, C., Shin, M., Ward, K., Rosenberg, L., Sitkovsky, M. V., Spiess, B. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.17.580835
“Recently, in a model of murine hepatocellular carcinoma, characterized by high intratumoral hypoxia and poor immunotherapeutic responses, the addition of the HIF inhibitor 32-134D to anti-PD1 therapy increased the rate of tumor eradication from 25% to 67% 66 .”
BackgroundResultZhong, J., Tian, L., Gou, Y., Zhao, P., Dong, X., Guo, M., Zhao, G., Li, A., Hao, A., He, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23682273
Zhong, J., Tian, L., Gou, Y., Zhao, P., Dong, X., Guo, M., Zhao, G., Li, A., Hao, A., He, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23682276
Hypoxia-Inducible Factors: Regulation and Therapeutic Potential
Lin, I., Chang, K., Cheng, F., Kanwar, R. K., Kamplikar, P., Kanwar, J. R., & Cheung, C. H. A. (2025) · Springer eBooks · doi:10.1007/978-981-96-1016-7_11 · Cited by 1
He, M., Wang, X., Xu, X., Wang, X., Wang, X., & Feng, X. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09185-7
Metadata
- Authors
- Salman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., Jackson, W., Dordai, D., Rudek, M. A., & Semenza, G. L.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Johns Hopkins University (US)
- Corresponding author
- Semenza, Gregg L.
- Venue
- Journal of Clinical Investigation
- Published
- 2022-05-02
- Volume
- 132
- Issue
- 9
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC9057582
- OpenAlex
- W4225257247
- Cited by
- 111
- References
- 99
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 18 · 2023: 29 · 2022: 10
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- American Cancer Society (RP-16-239-06-COUN)
- Armstrong Family Foundation (n/a)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- hepatocellular carcinoma, HIF-1α inhibition, HIF-2α inhibition, anti-PD-1 therapy, combination immunotherapy, tumor hypoxia, tumor immune microenvironment, tumor-associated macrophages, myeloid-derived suppressor cells, CD8+ T cells, natural killer cells, angiogenesis, glycolytic metabolism, immune evasion, antitumor immunity
- MeSH terms
- Animals, Hypoxia, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Neovascularization, Pathologic, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.